Roumell Asset Management Raised Its Paratek Pharmaceuticals (PRTK) Position by $1.26 Million; As Icici Bk LTD (IBN) Stock Declined, Shareholder New Vernon Capital Holdings Ii Lowered Stake by $1.83 Million

June 14, 2018 - By Dolores Ford

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Logo

Jim Roumell increased its stake in Paratek Pharmaceuticals Inc (PRTK) by 96.02% based on its latest 2018Q1 regulatory filing with the SEC. Roumell Asset Management Llc bought 96,668 shares as the company’s stock declined 24.82% with the market. The hedge fund run by Jim Roumell held 197,347 shares of the health care company at the end of 2018Q1, valued at $2.57 million, up from 100,679 at the end of the previous reported quarter. Roumell Asset Management Llc who had been investing in Paratek Pharmaceuticals Inc for a number of months, seems to be bullish on the $334.92 million market cap company. The stock increased 0.47% or $0.05 during the last trading session, reaching $10.6. About 150,469 shares traded. Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has declined 50.36% since June 14, 2017 and is downtrending. It has underperformed by 62.93% the S&P500. Some Historical PRTK News: 09/05/2018 – PARATEK – AS OF MARCH 31, 2018, HAD CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $184.3 MLN; 04/04/2018 – PARATEK PHARMACEUTICALS INC – PDUFA ACTION DATE IN OCTOBER 2018; 19/04/2018 – PARATEK PHARMACEUTICALS INC – NOTES WILL PAY INTEREST SEMIANNUALLY IN ARREARS ON MAY 1 AND NOVEMBER 1 OF EACH YEAR AT RATE OF 4.75% PER YEAR; 19/04/2018 – PARATEK PHARMACEUTICALS, PRICES $140M OF CONV SR SUB NOTES DUE; 18/04/2018 – Paratek Pharmaceuticals, Inc. Announces Proposed Private Offering of $125 Million of Convertible Senior Subordinated Notes due 2024; 09/05/2018 – PARATEK PHARMACEUTICALS ON TRACK FOR 1Q `19 OMADACYCLINE LAUNCH; 18/04/2018 – PARATEK PHARMACEUTICALS-INTENDS TO USE PROCEEDS, TOGETHER WITH EXISTING CAPITAL RESOURCES, TO FUND ONGOING AND FUTURE CLINICAL STUDIES OF OMADACYCLINE; 28/03/2018 – Paratek at HC Wainwright Global Biotechnology Conference Apr 9; 12/04/2018 – Paratek Pharmaceuticals Presenting New Data from Omadacycline Development Program at ECCMID 2018; 15/05/2018 – Armistice Capital Buys New 1.8% Position in Paratek

New Vernon Capital Holdings Ii Llc decreased its stake in Icici Bk Ltd (IBN) by 56.67% based on its latest 2018Q1 regulatory filing with the SEC. New Vernon Capital Holdings Ii Llc sold 228,180 shares as the company’s stock declined 14.41% with the market. The hedge fund held 174,433 shares of the commercial banks company at the end of 2018Q1, valued at $1.54 million, down from 402,613 at the end of the previous reported quarter. New Vernon Capital Holdings Ii Llc who had been investing in Icici Bk Ltd for a number of months, seems to be less bullish one the $27.49B market cap company. The stock decreased 1.17% or $0.1 during the last trading session, reaching $8.42. About 1.74 million shares traded. ICICI Bank Limited (NYSE:IBN) has declined 2.16% since June 14, 2017 and is downtrending. It has underperformed by 14.73% the S&P500. Some Historical IBN News: 16/03/2018 – NDTV: Comparison Of Bank Of India, SBI, ICICI Bank, HDFC Bank FD Interest Rates; 28/03/2018 – ICICI BANK SANCTIONED INR32.5B IN FACILITIES TO VIDEOCON 2012; 07/05/2018 – ICICI BANK-PROVISION MADE BY DEBITING RESERVES, SURPLUS WILL BE REVERSED, ACCOUNTED VIA P&L ACCOUNT OVER SUBSEQUENT QTRS OF FY 2019; 24/04/2018 – INDIA’S ICICI PRUDENTIAL LIFE INSURANCE COMPANY LTD ICIR.NS – MARCH QTR PROFIT 3.41 BLN RUPEES VS PROFIT OF 4.08 BLN RUPEES LAST YEAR; 28/03/2018 – ICICI BANK LTD ICBK.NS SAYS “THERE IS NO QUESTION OF ANY QUID PRO QUO/NEPOTISM/CONFLICT OF INTEREST AS IS BEING ALLEGED IN VARIOUS RUMOURS”; 10/05/2018 – FirstPost: ICICI-Vodafone loan row: Lok Ranjan, government’s nominee on bank board, transferred to Dept of Personnel; 12/04/2018 – Business Std.in: Sebi initiates probe into alleged corporate governance breaches at ICICI; 18/04/2018 – CBI QUESTIONS NUPOWER CFO BHUTA IN ICICI-VIDEOCON CASE:OFFICIAL; 04/04/2018 – India Unit News: ICICI Bank enables NRIs to send money through social media on its Money2India app; 02/04/2018 – ICICI BANK LTD CLARIFIES ON NEWS ITEM THAT SAID ED INITIATES ENQUIRY INTO ICICI-VIDEOCON LOAN CASE

Roumell Asset Management Llc, which manages about $293.14 million and $45.42M US Long portfolio, decreased its stake in Liquidity Services Inc (NASDAQ:LQDT) by 219,900 shares to 888,328 shares, valued at $5.77M in 2018Q1, according to the filing.

Investors sentiment increased to 2.31 in Q1 2018. Its up 1.40, from 0.91 in 2017Q4. It is positive, as 16 investors sold PRTK shares while 13 reduced holdings. 22 funds opened positions while 45 raised stakes. 20.55 million shares or 6.29% more from 19.34 million shares in 2017Q4 were reported. Boston Prns has 133,682 shares. Barclays Public Ltd Com invested in 5,907 shares. Broadfin Cap Lc holds 0.97% or 477,607 shares. Brown Brothers Harriman And Co holds 0.02% or 287,902 shares in its portfolio. Rhumbline Advisers has invested 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Cubist Systematic Strategies Lc holds 0.01% or 11,274 shares in its portfolio. Alyeska Inv Group Limited Partnership stated it has 1.43 million shares. Ellington Group Limited Liability Corporation reported 25,300 shares. Hennessy Advsrs accumulated 25,490 shares. Highland LP stated it has 0.64% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Alps Advsr Inc, a Colorado-based fund reported 41,707 shares. 40,617 were accumulated by California State Teachers Retirement Sys. General Amer Invsts Incorporated accumulated 308,864 shares or 0.38% of the stock. 28,356 were reported by Old West Mgmt Llc. Northern Tru accumulated 361,406 shares or 0% of the stock.

More notable recent Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) news were published by: Streetinsider.com which released: “Paratek Pharmaceuticals (PRTK) Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting …” on June 11, 2018, also Nasdaq.com with their article: “Paratek Demonstrates Breadth of Omadacycline Clinical and Microbiological Data at ASM Microbe 2018” published on June 07, 2018, Seekingalpha.com published: “Integrated BioSci Research On Cidara Therapeutics: What’s In Store For This Promising Antibiotic Innovator?” on June 08, 2018. More interesting news about Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) were released by: Prnewswire.com and their article: “Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018” published on June 06, 2018 as well as Nasdaq.com‘s news article titled: “Paratek Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting Efficacy of Omadacycline …” with publication date: June 11, 2018.

Among 10 analysts covering Paratek Pharmaceuticals (NASDAQ:PRTK), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Paratek Pharmaceuticals had 27 analyst reports since July 23, 2015 according to SRatingsIntel. Leerink Swann maintained Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) rating on Tuesday, July 18. Leerink Swann has “Buy” rating and $3700 target. As per Tuesday, April 4, the company rating was maintained by Wedbush. As per Friday, March 2, the company rating was maintained by H.C. Wainwright. The stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) earned “Hold” rating by Zacks on Saturday, August 8. H.C. Wainwright maintained it with “Buy” rating and $4300 target in Tuesday, July 18 report. The stock has “Buy” rating by Robert W. Baird on Tuesday, October 24. The stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has “Buy” rating given on Thursday, July 23 by Gabelli. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, August 23 report. The company was upgraded on Tuesday, September 22 by Zacks. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, November 8 report.

Analysts await ICICI Bank Limited (NYSE:IBN) to report earnings on July, 26. They expect $0.07 EPS, down 30.00% or $0.03 from last year’s $0.1 per share. IBN’s profit will be $228.56 million for 30.07 P/E if the $0.07 EPS becomes a reality. After $0.05 actual EPS reported by ICICI Bank Limited for the previous quarter, Wall Street now forecasts 40.00% EPS growth.

Among 7 analysts covering ICICI Bank (NYSE:IBN), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. ICICI Bank had 11 analyst reports since August 19, 2015 according to SRatingsIntel. The firm has “Sell” rating by Zacks given on Tuesday, August 25. Standpoint Research upgraded ICICI Bank Limited (NYSE:IBN) rating on Wednesday, August 26. Standpoint Research has “Hold” rating and $12.0 target. The company was upgraded on Thursday, September 3 by Zacks. The firm has “Buy” rating given on Tuesday, January 16 by Morgan Stanley. The firm has “Buy” rating given on Friday, October 21 by UBS. The firm has “Buy” rating by Jefferies given on Monday, October 30. The firm earned “Buy” rating on Monday, October 24 by Goldman Sachs. The firm has “Neutral” rating by Goldman Sachs given on Tuesday, May 3. Credit Suisse upgraded the shares of IBN in report on Thursday, April 21 to “Outperform” rating. The stock has “Buy” rating by Goldman Sachs on Monday, September 14.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>